NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis $1.40 +0.01 (+0.72%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.05 (+3.21%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About MacroGenics Stock (NASDAQ:MGNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MacroGenics alerts:Sign Up Key Stats Today's Range$1.36▼$1.4850-Day Range$1.06▼$1.9652-Week Range$0.99▼$5.77Volume248,489 shsAverage Volume791,338 shsMarket Capitalization$88.33 millionP/E RatioN/ADividend YieldN/APrice Target$5.71Consensus RatingHold Company OverviewMacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Read More… MacroGenics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreMGNX MarketRank™: MacroGenics scored higher than 77% of companies evaluated by MarketBeat, and ranked 245th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingMacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageMacroGenics has only been the subject of 4 research reports in the past 90 days.Read more about MacroGenics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MacroGenics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.51% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in MacroGenics has recently increased by 7.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.61 Percentage of Shares Shorted10.51% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in MacroGenics has recently increased by 7.22%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.81 News SentimentMacroGenics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for MacroGenics this week, compared to 7 articles on an average week.MarketBeat Follows2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have not sold or bought any company stock.Percentage Held by Insiders13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MacroGenics' insider trading history. Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGNX Stock News HeadlinesWhat is B. Riley's Estimate for MacroGenics Q2 Earnings?May 24, 2025 | americanbankingnews.comZacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion TechnologiesMay 23, 2025 | nasdaq.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. May 29, 2025 | Altimetry (Ad)B. Riley Cuts MacroGenics (NASDAQ:MGNX) Price Target to $3.00May 23, 2025 | americanbankingnews.com6MGNX : 4 Analysts Assess Macrogenics: What You Need To KnowMay 20, 2025 | benzinga.comMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsMay 16, 2025 | finanznachrichten.deEarnings Release: Here's Why Analysts Cut Their MacroGenics, Inc. (NASDAQ:MGNX) Price Target To US$4.50May 16, 2025 | finance.yahoo.comMacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comSee More Headlines MGNX Stock Analysis - Frequently Asked Questions How have MGNX shares performed this year? MacroGenics' stock was trading at $3.25 at the beginning of 2025. Since then, MGNX shares have decreased by 56.5% and is now trading at $1.4150. View the best growth stocks for 2025 here. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) announced its quarterly earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.04. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to analyst estimates of $9.59 million. MacroGenics had a negative trailing twelve-month return on equity of 89.42% and a negative net margin of 69.07%. Who are MacroGenics' major shareholders? MacroGenics' top institutional investors include Armistice Capital LLC (9.98%), Acadian Asset Management LLC (3.66%), Connor Clark & Lunn Investment Management Ltd. (1.29%) and Jacobs Levy Equity Management Inc. (1.05%). Insiders that own company stock include Target N V Biotech, James Karrels, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL). Company Calendar Last Earnings5/13/2025Today5/29/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGNX CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees430Year Founded2000Price Target and Rating Average Stock Price Target$5.71 High Stock Price Target$14.00 Low Stock Price Target$2.00 Potential Upside/Downside+308.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.06 million Net Margins-69.07% Pretax Margin-69.07% Return on Equity-89.42% Return on Assets-38.57% Debt Debt-to-Equity RatioN/A Current Ratio3.75 Quick Ratio3.69 Sales & Book Value Annual Sales$152.43 million Price / Sales0.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.57Miscellaneous Outstanding Shares63,090,000Free Float55,671,000Market Cap$88.33 million OptionableOptionable Beta2.20 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:MGNX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.